Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 211,944 shares at $5.01 ($1.1M) on 2024-11-29, disclosed to the SEC on 2024-12-02.
Scheduled sale ($1.1M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.00 | 12,936 | $65K | 6.1% |
| 2 | $5.01 | 98,704 | $495K | 46.6% |
| 3 | $5.01 | 98,704 | $495K | 46.6% |
| 4 | $5.00 | 1,600 | $8K | 0.8% |
| Total | $5.01 avg | 211,944 | $1.1M | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |